S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
He Is Giving Away Bitcoin (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
He Is Giving Away Bitcoin (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
He Is Giving Away Bitcoin (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
He Is Giving Away Bitcoin (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Free Trial
NASDAQ:KIN

Kindred Biosciences (KIN) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)
Free KIN Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$9.24
▼
$9.26
50-Day Range
$9.08
▼
$9.25
52-Week Range
$3.46
▼
$9.28
Volume
178,496 shs
Average Volume
840,890 shs
Market Capitalization
$420.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
KIN stock logo

About Kindred Biosciences Stock (NASDAQ:KIN)

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

KIN Stock News Headlines

March 22, 2024 | mirror.co.uk
Tory party donor Frank Hester to be investigated for 'racist comments' by West Yorkshire Police
February 23, 2024 | health.usnews.com
Kindred Hospital East Greensboro
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
January 22, 2024 | reuters.com
Japan's Sony terminates $10 bln Zee India merger
January 22, 2024 | markets.businessinsider.com
European Shares Edge Higher With ECB Meeting In The Spotlight
January 22, 2024 | markets.businessinsider.com
Earnings Optimism May Contribute To Continued Strength On Wall Street
December 17, 2023 | latimes.com
Honoree: Nanxi Liu
November 8, 2023 | finance.yahoo.com
Global Companion Animal Pharmaceuticals Market Size To Worth USD 27.16 Billion by 2032 | CAGR of 5.7%
April 19, 2024 | Gold Safe Exchange (Ad)
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
October 7, 2023 | health.usnews.com
Kindred Hospital-Dayton
September 21, 2023 | tmcnet.com
Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development
August 17, 2023 | bizjournals.com
How a small Peninsula company plans to take a big bite out of the pet drug market
June 11, 2023 | es-us.finanzas.yahoo.com
Pet Cancer Therapeutics Global Market Report 2023
May 11, 2023 | marketwatch.com
Oral COVID-19 Vaccine Market 2023 Expected Highest Growth and Precise Outlook | Pfizer, CanSino Biologics, Kindred Biosciences
May 5, 2023 | marketwatch.com
Pet Medication Market Size and Forecast to 2031
May 5, 2023 | health.usnews.com
Kindred Hospital-New Jersey Morris County
April 26, 2023 | uk.finance.yahoo.com
Veterinary Dermatology Drugs Global Market Report 2023
April 25, 2023 | health.usnews.com
Kindred Hospital Chicago-Northlake
April 19, 2023 | usnews.com
Kindred High School
April 19, 2023 | thestreet.com
Kindred Bio CEO: Expect 3 Dynamic Dog Drugs by 2015
March 31, 2023 | theguardian.com
Kindred review – a reductive, hollow view of Black trauma
March 30, 2023 | marketwatch.com
Canine Atopic Dermatitis Market Share and Forecast till 2031
March 28, 2023 | health.usnews.com
Kindred Hospital-Ontario
March 22, 2023 | marketwatch.com
Companion Animal Pharmaceuticals Market worth $19.6 billion | MarketsandMarkets
March 7, 2023 | marketwatch.com
The Pet Medication study examines a number of direct and indirect factors that could affect the supply and demand dynamics in this market
March 6, 2023 | msn.com
How De La Soul's 3 Feet High and Rising broadened the possibilities of hip hop
March 3, 2023 | marketwatch.com
Pet Medication Market 2023 | Global Industry Report Forecast 2029
See More Headlines
Receive KIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kindred Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/05/2021
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KIN
CUSIP
N/A
CIK
1561743
Web
kindredbio.com
Phone
(650) 701-7901
Fax
N/A
Employees
63
Year Founded
2013

Profitability

EPS (Most Recent Fiscal Year)
($0.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-21,800,000.00
Net Margins
-529.26%
Pretax Margin
N/A
Return on Equity
-54.19%
Return on Assets
-39.76%

Debt

Debt-to-Equity Ratio
0.19
Current Ratio
7.02
Quick Ratio
7.02

Sales & Book Value

Annual Sales
$42.16 million
Price / Sales
9.97
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.75 per share
Price / Book
5.29

Miscellaneous

Outstanding Shares
45,462,000
Free Float
N/A
Market Cap
$420.52 million
Optionable
Optionable
Beta
1.30

Social Links

20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Key Competitors

View All Competitors

KIN Stock Analysis - Frequently Asked Questions

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences, Inc. (NASDAQ:KIN) released its quarterly earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.04. The biopharmaceutical company had revenue of $3.54 million for the quarter, compared to the consensus estimate of $8.12 million. Kindred Biosciences had a negative trailing twelve-month return on equity of 54.19% and a negative net margin of 529.26%.

What other stocks do shareholders of Kindred Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include bluebird bio (BLUE), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), OPKO Health (OPK), TherapeuticsMD (TXMD) and Agile Therapeutics (AGRX).

This page (NASDAQ:KIN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Urgent alert: open this for a huge profit potential
Timothy Sykes
The #1 Crypto for 2024
InvestorPlace